Ostendorf L, Burns M, Durek P, et al. - This study intended to present the use of daratumumab that induced substantial clinical responses in two patients with life-threatening lupus, with the clinical responses sustained by maintenance therapy with belimumab, an antibody to B-cell activating factor. It was shown that a significant depletion of long-lived plasma cells, reduction of interferon type I activity, and down-regulation of T-cell transcripts correlated with chronic inflammation were documented.